# US 2019/0315720 A1 · Hydroxyalkyl-substituted triazole derivatives and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315720 A1
- Document ID: US20190315720A1
- Status: Published application
- Kind: A1
- Application number: 16/343,150
- Filed: 2017-10-16
- Published: 2019-10-17
- Earliest claimed: 2016-10-20
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Chantal FUERSTNER; Marie-Pierre COLLIN-KROEPELIN; Peter KOLKHOF; Thomas NEUBAUER; Elisabeth POOK; Heiko SCHIRMER; Carsten SCHMECK; Pierre WASNAIRE; Matthias Beat WITTWER
- Web page: https://patentgrep.com/patent/US20190315720A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- C07D 403/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel 3-(hydroxyalkyl)-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and/or cardiovascular diseases.

## Claims

### Claim 1

A compound of formula (I)
in which
R1 represents a group of the formula
in which
#1 represents the point of attachment to the rest of the molecule,
R2 represents a group selected from trifluoromethyl and (C2-C4)-alkyl, wherein any (C2-C4)-alkyl group is optionally substituted with up to three fluorine atoms,
R3 represents (C1-C4)-alkyl,
wherein any (C1-C4)-alkyl group is optionally substituted with up to three fluorine atoms,
Ar represents a phenyl group or a 5- or 6-membered heteroaryl group attached via a ring carbon atom having one, two or three ring heteroatoms selected from N, O and S,
wherein any phenyl group and any 5- or 6-membered heteroaryl group are each optionally substituted, identically or differently, with one or two groups selected from halogen, nitro, cyano, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylsulfanyl, (C1-C4)-alkoxycarbonyl, aminocarbonyl and —S(═O)2NH2,
wherein said (C1-C4)-alkyl group, said (C1-C4)-alkoxy group and said (C1-C4)-alkylsulfanyl group are each optionally substituted with up to three fluorine atoms.
And/or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 2 (depends on 1)

A compound of formula (I) according to claim 1, wherein
R1 represents a group of the formula
in which
#1 represents the point of attachment to the rest of the molecule,
R2 represents a group selected from trifluoromethyl and (C2-C4)-alkyl, wherein any (C2-C4)-alkyl group is optionally substituted with up to three fluorine atoms,
R3 represents (C1-C4)-alkyl,
wherein any (C1-C4)-alkyl group is optionally substituted with up to three fluorine atoms,
Ar represents a group selected from phenyl or pyridyl,
wherein any phenyl group and any pyridyl group is each optionally substituted, identically or differently, with one or two groups selected from halogen, cyano, (C1-C4)-alkyl, (C1-C4)-alkoxy and aminocarbonyl,
wherein said (C1-C4)-alkyl group or said (C1-C4)-alkoxy group are each optionally substituted with up to three fluorine atoms,
and/or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 3 (depends on 1)

A compound of formula (I) according to claim 1, wherein
R1 represents a group of the formula
in which
#1 represents the point of attachment to the rest of the molecule,
R2 represents an ethyl group,
R3 represents a methyl group,
Ar represents a group of the formula
in which
#2 represents the point of attachment to the nitrogen atom,
And/or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 4 (depends on 1)

A compound of formula (I) according to claim 1, wherein
R1 represents a group of the formula
in which
#1 represents the point of attachment to the rest of the molecule,
R2 represents a group selected from trifluoromethyl and ethyl,
R3 represents a methyl group,
Ar represents a group of the formula
in which
#2 represents the point of attachment to the nitrogen atom,
And/or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

### Claim 5 (depends on 1)

A method of preparing a compound of formula (I) according to claim 1 said method comprising
[A] allowing an intermediate compound of formula (II):
in which
R1 represents a group of the formula
in which
#1, R2 and R3 are as defined for the compound of formula (I),
to react with a compound of formula (III):
in which
Ar is as defined for the compound of formula (I),
in the presence of a copper catalyst and an amine base thereby giving a compound of formula (I-A):
in which
R1 represents a group of the formula
in which
#1, R2 and R3 are as defined for the compound of formula (I),
Ar is as defined for the compound of formula (I),
or
[B] allowing an intermediate compound of formula (IV):
in which
Ar is as defined for the compound of formula (I),
to react with a compound of formula (V):
in which
R2 is as defined for the compound of formula (I),
X represents chloride, bromide or iodide,
to give an intermediate compound of formula (VI):
in which
R2 and Ar are as defined for the compound of formula (I),
which is then allowed to react with a suitable reduction reagent, optionally sodium borohydride, thereby giving a compound of formula (I-B):
in which
R2 and Ar are as defined for the compound of formula (I),
or
[C] allowing an intermediate compound of formula (VII):
in which
R3 and Ar are as defined for the compound of formula (I),
to react with a compound of formula (VIII):
in which
X represents chloride, bromide or iodide,
thereby giving a compound of formula (I-C):
in which
R3 and Ar are as defined for the compound of formula (I),
each [A], [B] and [C] optionally followed, where appropriate, by (i) separating the compounds of formula (I) thus obtained into their respective enantiomers or diastereomers, and/or (ii) converting the compounds of formula (I) into their respective hydrates, solvates, salts and/or hydrates or solvates of the salts by treatment with the corresponding solvents and/or acids or bases.

### Claim 6 (depends on 1)

Compound as defined in claim 1 for treatment and/or prevention of diseases.

### Claim 7 (depends on 1)

Compound as defined in claim 1 for use in a method for treatment and/or prevention of acute and chronic kidney diseases comprising diabetic nephropathy, acute and chronic heart failure, preeclampsia, peripheral arterial disease (PAD) and coronary microvascular dysfunction (CMD), Raynaud's syndrome, and/or dysmenorrhea.

### Claim 8 (depends on 1)

A compound as defined in claim 1 for manufacture of a pharmaceutical composition for the treatment and/or prevention of acute and chronic kidney diseases comprising diabetic nephropathy, acute and chronic heart failure, preeclampsia, peripheral arterial disease (PAD) and coronary microvascular dysfunction (CMD), Raynaud's syndrome, and/or dysmenorrhea.

### Claim 9 (depends on 1)

Pharmaceutical composition comprising a compound as defined in claim 1 and one or more pharmaceutically acceptable excipients.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9 further comprising one or more additional therapeutic agents selected from the group consisting of diuretics, angiotensin All antagonists, ACE inhibitors, beta-receptor blockers, mineralocorticoid receptor antagonists, organic nitrates, NO donors, activators and stimulators of the soluble guanylate cyclase, and positive-inotropic agents.

### Claim 11 (depends on 9)

The pharmaceutical composition as defined in claim 9 for treatment and/or prevention of acute and chronic kidney diseases comprising diabetic nephropathy, acute and chronic heart failure, preeclampsia, peripheral arterial disease (PAD) and coronary microvascular dysfunction (CMD), Raynaud's syndrome, dysmenorrhea, cardiorenal syndrome, hypervolemic and euvolemic hyponatremia, liver cirrhosis, ascites, edema and/or the syndrome of inadequate ADH secretion (SIADH).

### Claim 12 (depends on 1)

Method for treatment and/or prevention of acute and chronic kidney diseases comprising diabetic nephropathy, acute and chronic heart failure, preeclampsia peripheral arterial disease (PAD) and coronary microvascular dysfunction (CMD), Raynaud's syndrome, and/or dysmenorrhea in a human or other mammal, comprising administering to a human or other mammal in need thereof a therapeutically effective amount of one or more compounds as defined in claim 1, or of a pharmaceutical composition thereof.
